-
Stocks Making the Biggest Moves Midday: Uber, DraftKings, Seagen, Activision Blizzard and More
These are the stocks posting the largest moves in midday trading.
-
Johnson & Johnson Says COVID-19 Booster Provides Strong Response
Johnson & Johnson released data showing that a booster dose to its one-shot coronavirus vaccine provides a strong immune response
-
What to Watch Today: Dow Set to Rebound After Monday's Sharp Decline
The Dow was set to rebound after slumping more than 600 points amidst Wall Street’s September slide.
-
5 Things to Know Before the Stock Market Opens Tuesday
The Dow was set to rebound after slumping more than 600 points amidst Wall Street’s September slide.
-
Stocks Making the Biggest Moves in the Premarket: Uber, Johnson & Johnson, Apple and More
These are the stocks posting the largest moves in premarket trading.
-
J&J Says 2nd Dose of Its COVID-19 Vaccine Boosts Protection
Johnson & Johnson released data showing that a booster dose to its one-shot coronavirus vaccine provides a strong immune response months after people receive a first dose.
-
J&J Says Covid Booster Shot Is 94% Effective in the U.S. When Given Two Months After First Dose
A J&J booster dose given six months out from the first shot appears to be potentially even more protective against Covid, the company added.
-
Pfizer Says Its Covid Vaccine Is Safe and Generates Robust Immune Response in Kids Ages 5 to 11
Pfizer and BioNTech tested a two-dose regimen of 10 micrograms — about a third the dosage used for teens and adults — administered three weeks apart.
-
Fauci Defends FDA Panel, Says It Didn't Make a Mistake Rejecting Booster Covid Shots for All Americans
The comments from Fauci come as the FDA advisory committee voted on Friday against giving third shots of Pfizer’s vaccine to the general U.S. population.
-
A Key Part of Biden's Plan to Combat Covid Is at Risk as FDA Meets to Debate Booster Shots
A key FDA panel meets Friday to debate and vote at around 2:30 p.m. ET on Pfizer and BioNTech’s application to offer booster shots to the general public.
-
Pfizer CEO Says Covid Vaccine Data for Kids Under Age 5 May Come in Late October
“Then, it is up to the FDA to take their time, and then make a decision,” Pfizer CEO Albert Bourla said.
-
FDA Says It Is ‘Working Around the Clock' to Support Covid Vaccine Approvals for Kids Under Age 12
Federal regulators are “eager to see our children and grandchildren vaccinated against COVID-19 as soon as possible,” the agency said.
-
Stocks Making the Biggest Moves Midday: Netflix, Boeing, State Street and More
These are the stocks posting the largest moves in midday trading.
-
What to Watch Today: Wall Street Looks Steady After Last Week's Delta-Driven Covid Concerns
U.S. stock futures were flat Tuesday after a much weaker-than-expected August jobs report weighed on Wall Street on Friday.
-
Stocks Making the Biggest Moves Premarket: JD.com, Boeing, Moderna, Spotify and More
These are the stocks posting the largest moves in premarket trading.
-
Dow Drops 260 Points as Investors Grow Concerned About Delta Variant's Impact on Economic Recovery
The Dow Jones Industrial Average fell on Tuesday amid lingering concerns about the delta variant’s impact on the economic reopening.
-
Pfizer Covid Booster Shots Will Likely Be Ready Sept. 20, But Moderna May Be Delayed, Fauci Says
Dr. Anthony Fauci said third Pfizer vaccine doses will likely be ready by Sept. 20, but approval for a Moderna booster may be delayed.
-
Companies: $26B Settlement of Opioid Lawsuits to Move Ahead
Four companies say they’ll move ahead with a $26 billion settlement of lawsuits over the opioid crisis.
-
Dr. Scott Gottlieb Says People Who Had Covid Won't Be Immune Forever, Should Get Vaccinated
Natural Covid immunity is likely “not going to last in perpetuity,” former FDA chief Dr. Scott Gottlieb told CNBC on Wednesday.
-
Nearly 1 Million Covid Booster Shots Have Already Been Administered in the U.S., CDC Data Shows
It’s unclear if all the extra doses the CDC reported were administered in immunocompromised people.
Trending
